As­traZeneca stocks up on Calquence am­mu­ni­tion for big BTK ri­val­ry with J&J, Ab­b­Vie

Catch­ing up with J&J and Ab­b­Vie on the BTK in­hibitor front, As­traZeneca says Calquence has hit a home run in a Phase III tri­al for first-line chron­ic lym­pho­cyt­ic leukemia.

At an in­ter­im analy­sis, re­searchers say the drug, when com­bined with Roche’s Gazy­va (obin­u­tuzum­ab), has al­ready demon­strat­ed a pro­gres­sion-free sur­vival ben­e­fit over the chemo-based reg­i­men fea­tur­ing chlo­ram­bu­cil and obin­u­tuzum­ab. The pri­ma­ry end­point win was both sta­tis­ti­cal­ly sig­nif­i­cant and clin­i­cal­ly mean­ing­ful, the com­pa­ny says, with­out dis­clos­ing any num­bers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.